Abstract: A therapeutic combination of a compound having antiestrogenic activity and a CDK4/6 inhibitor is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting mimicking diet for a period of 24-190 hours while the patient is being treated with the therapeutic combination, in which the compound having antiestrogenic activity can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor degrader (SERD) or an aromatase inhibitor (AI).

Abstract: The present invention relates to at least one reduced caloric intake cycle and at least one immunotherapeutic agent for use in the treatment of cancer. Preferably the cancer is characterized by resistance or partial response to the treatment with at least one immunotherapeutic agent.

Abstract: The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising compounds of formula (I), to their medical use and to their process of preparation.

Abstract: The present invention relates to the use of fasting mimicking diet (FMD) to inhibit growth and/or kill cancer stem cells (CSCs) in combination with at least one anticancer agent selected from: an AKT inhibitor, an hexokinase inhibitor, a PI3K inhibitor, a combination of a PI3K inhibitor and a CDK4/6 inhibitor, or a combination of a mTOR inhibitor and a PI3K inhibitor. FMD in combination with the anticancer agent is particularly effective in the treatment of triple negative breast cancer (TNBC) and reduces cancer stem cells (CSCs) escape pathways. The invention further relates to a method to identify starvation escape pathways in cancer cells, which can be targeted by drugs.

Abstract: The present invention relates to at least one modulator of PP2A or at least one modulator of PP2A-like phosphatase or at least one modulator of PP2A and PP2A-like phosphatase or a combination of said modulators for use in the treatment of a disease characterized by an alteration in the DNA damage response. The present invention also relates to a method to identify a subject to be treated with a PP2A modulator comprising detecting in the genome of said patient a mutation in PP2A.

Abstract: A cell stretching device including a cell chamber having upper and lower portions is disclosed. The lower portion has fixing means for fixing a deformable cell substrate (S) to the cell chamber and defining a stretching region inside the chamber at the lower portion. The upper portion has stretching means movable relative to the chamber and acting on the cell substrate (S) and a support element for holding the stretching means and a driving unit coupled to the upper portion of the cell chamber and engageable to the stretching means for mechanically controlling and regulating the movement of the stretching means relative to the cell chamber. The stretching means include clip members operating inside the stretching region which are configured to clamp the cell substrate (S) at a clamping contact point and to stretch the cell substrate (S) in response to the movement.

Abstract: The present invention relates to small RNAs, inhibitors thereof, inhibitors of enzymes producing thereof, and their use to modulate the response of a cell to a DNA damaging event. The invention concerns also a method to detect the presence or quantify DNA damage.

Abstract: The present invention refers to a method for obtaining a CRISPR-Cas system sgRNA library and to the use of the library to select individual cell knock outs that survive under a selective pressure and/or to identify the genetic basis of one or more biological or medical symptoms exhibited by a subject and/or to knocking out in parallel every gene in the genome.

Abstract: The invention relates to inhibitors of the urokinase-type plasminogen activator receptor (uPAR). The generated inhibitors are bivalent uPAR-ligands containing the receptor binding domains of the extracellular protease urokinase-type plasminogen activator (uPA) and of the extracellular matrix protein vitronectin (VN), in different configurations, linked by a scaffold. The present invention also refers to the above molecules for use as a medicament, in particular for treatment of cancer, and for diagnostic purposes.